| Whole-body MRI for the staging and follow-up of patients with metastasis. | |
| | |
MedLine Citation:
|
PMID: 19457631 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The advent of whole-body MRI (WB-MRI) has introduced tumor imaging with a systemic approach compared to established sequential, multi-modal diagnostic algorithms. Hardware innovations, such as the introduction of multi-receiver channel whole-body scanners at 1.5 T and recently 3T, combined with acquisition acceleration techniques, have made high resolution WB-MRI clinically feasible. Now, a dedicated assessment of individual organs with various soft tissue contrast, spatial resolution and contrast media dynamics can be combined with whole-body anatomic coverage in a multi-planar imaging approach. More flexible protocols, e.g. including T1-weighted TSE- and STIR-imaging, dedicated lung imaging or dynamic contrast-enhanced studies of the abdomen can be performed within less than 45 min. For initial tumor staging PET-CT as a competing whole-body modality in oncologic imaging has proved more accurate for the definition of T-stage and lymph node assessment, using the additional metabolic information of PET for the assessment of tumor viability and therapy response. However, new applications, such as MR-whole-body diffusion imaging, may significantly increase sensitivity in near future. WB-MRI has shown advantages for the detection of distant metastatic disease, especially from tumors frequently spreading to the liver or brain and it is especially useful as a radiation-free alternative for the surveillance of tumor patients with multiple follow-up exams. Furthermore, it has been introduced as a whole-body bone marrow screening application. Within this context WB-MRI is highly accurate for the detection of skeletal metastases and staging of hematologic diseases, such as multiple myeloma or lymphoma. This article summarizes recent developments and applications of WB-MRI and highlights its performance within the scope of systemic oncologic staging and surveillance. |
| | |
Authors:
|
Gerwin P Schmidt; Maximilian F Reiser; Andrea Baur-Melnyk |
Publication Detail:
|
Type: Journal Article; Review Date: 2009-05-19 |
Journal Detail:
|
Title: European journal of radiology Volume: 70 ISSN: 1872-7727 ISO Abbreviation: Eur J Radiol Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-06-15 Completed Date: 2009-08-26 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8106411 Medline TA: Eur J Radiol Country: Ireland |
Other Details:
|
Languages: eng Pagination: 393-400 Citation Subset: IM |
Affiliation:
|
Department of Clinical Radiology, University Hospitals Grosshadern, Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377 München, Germany. gerwin.schmidt@med.uni-muenchen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Follow-Up Studies Humans Magnetic Resonance Imaging / methods* Neoplasm Metastasis / pathology* Neoplasm Staging / methods* Neoplasms / diagnosis* Radiopharmaceuticals / diagnostic use Whole Body Imaging / methods* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Transiently reduced water diffusion in the corpus callosum in infants with benign partial epilepsy i...
Next Document: Assessement of rheumatic diseases with computational radiology: Current status and future potential.